4-IBP is selective 1 agonist with Ki of 17 nM and 252 nM for 2 receptor

Product information

CAS Number: 155798-08-6

Molecular Weight: 420.29

Formula: C19H21IN2O

Chemical Name: N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide

Smiles: O=C(NC1CCN(CC2C=CC=CC=2)CC1)C1C=CC(I)=CC=1

InChiKey: HELCSESNNDZLFM-UHFFFAOYSA-N

InChi: InChI=1S/C19H21IN2O/c20-17-8-6-16(7-9-17)19(23)21-18-10-12-22(13-11-18)14-15-4-2-1-3-5-15/h1-9,18H,10-14H2,(H,21,23)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 20 mg/mL (47.59 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

4-IBP decreases the migration levels of various types of cancer cells, including C32 melanoma, U373-MG glioblastoma, A549 NSCLC, and PC3 prostate cancer cells. 4-IBP modifies the sensitivity of U373-MG cells in vitro to proapoptotic lomustin and proautophagic temozolomide, and markedly decreases the expression of two proteins involved in drug resistance: glucosylceramide synthase and Rho guanine nucleotide dissociation inhibitor[1].

In Vivo:

In vivo, 4-IBP increases the antitumor effects of temozolomide and irinotecan in immunodeficient mice that are orthotopically grafted with invasive cancer cells[1].

References:

1. Mégalizzi V, et al. Neoplasia. 2007, 9(5):358-69.

Products are for research use only. Not for human use.